Acrivon's 368 Program Delivers, Stock Surges 31% on Clinical Milestone Announcements

Biotech stock Acrivon Therapeutics is making waves in the market following strong interim data expected from its flagship programs. The company will broadcast clinical findings tomorrow (January 8, 2026) showcasing progress on its 368 candidate alongside early results from a secondary asset, sparking investor enthusiasm with shares climbing 31.44% to $3.01 yesterday, then pushing further to $3.45 in extended trading.

The 368 Story: Clinical Momentum Building

At the heart of Acrivon’s pipeline sits 368—a selective inhibitor targeting CHK1 and CHK2 pathways—being evaluated in a Phase 2b registrational study for endometrial cancer patients. The regulatory pathway appears favorable: the FDA has already assigned Fast Track status recognizing the drug’s potential as a standalone treatment. Notably, the agency granted Breakthrough Device designation for the OncoSignature predictive test, designed to identify which patients will respond best to 368 therapy.

This companion diagnostic approach represents an emerging trend in oncology—pairing precision detection tools with targeted therapeutics to optimize treatment outcomes and reduce trial failure rates.

Secondary Program Shows Early Promise

Beyond the 368 focus, Acrivon is unveiling preliminary data from ACR-2316, a WEE1/PKMYT1 inhibitor now progressing through Phase 1 testing. Early signals suggest the compound engages its target even at lower doses, with observed tumor shrinkage appearing at dose level 3. The mechanism of action targets multiple cell cycle kinases—CDK1, CDK2, and PLK1—to trigger cancer cell death through apoptosis.

Technology Platform Driving Pipeline

Underlying both programs is Acrivon’s proprietary AP3 platform, a generative phosphoproteomics system enabling systematic drug design by measuring compound-specific effects within whole cells. Tomorrow’s announcements will also introduce a novel preclinical candidate sourced from this AP3-driven research approach, suggesting the platform’s expanding utility.

Financial Runway Intact

As of late September 2025, Acrivon maintained $134.4 million in cash and liquid securities, positioned to fund operations through Q2 2027. This runway provides sufficient capital runway for advancing 368 through late-stage development and supporting the broader pipeline progression.

Market Context

Trading over the past twelve months ranged between $1.01 and $3.06, with yesterday’s close at $3.01 followed by overnight appreciation to $3.45—a sharp move reflecting investor confidence in the clinical narrative emerging from tomorrow’s webcast.